Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The drugs account for $41 billion in annual Medicare spending, the Biden administration said.

Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...